MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors or Leukemia

MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors or Leukemia - MEK114375

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38447

Enrollment

Registered

2013-03-13

Start date

2013-11-27

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Treatment with trametinib.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Currently participating in trametinib study and is receiving treatment with trametinib. • Currently receiving clinical benefit as determined by the investigator from previous treatment with trametinib either as monotherapy or as part of a combination treatment regimen.

Exclusion criteria

Exclusion criteria: • Local access to commercially available GSK1120212. • Current use of a prohibitive medication(s) as listed in the protocol (section 6.2). • Bazett-corrected interval >=501 msec at the time of transition to this study. • LVEF

Design outcomes

Primary

Measure	Time frame
None.	—

Secondary

Measure	Time frame
None.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)